In comparison to healthy controls, serum levels of SEMA3A, SEMA3C and SEMA4D were significantly higher, whereas SEMA5A and SEMA7A were significantly lower in NAFLD patients, as shown in Figure 1 and in Table S1. This evidence concerns the gene SEMA3A and metabolic dysfunction-associated steatotic liver disease.